Juvenile Idiopathic Arthritis Associated Uveitis
Conditions
Keywords
Biologics, JIA-U, Uveitis, Pediatrics, adalimumab
Brief summary
Juvenile Idiopathic Arthritis (JIA) remains the most common systemic disorder associated with pediatric uveitis. Studies estimate that 28-67% of patients with JIA-associated uveitis develop ocular complications, with 12% developing poor visual outcome. The only means of improving long term effects of uveitis, is early and aggressive anti-inflammatory treatment, including biologics.
Detailed description
Juvenile Idiopathic Arthritis (JIA) remains, globally, the most common systemic disorder associated with pediatric uveitis consisting 75% of anterior uveitis cases (AU)1. In a cohort study from Cairo University Pediatric Hospital, JIA accounted for 39% of all cases of pediatric uveitis (unpublished data). Studies estimate that 28-67% of patients with JIA-U develop ocular complications, with 12% developing poor visual outcome2,3,4. Thus, early and aggressive anti-inflammatory treatment is the only means of improving long term effects of uveitis5-7. In 2019, the American College of Rheumatology/Arthritis Foundation recommended, that in severe, active, chronic AU or in the presence of sight-threatening complications, methotrexate (MTX) and a monoclonal antibody Tumor Necrosis Factor inhibitor (TNFi) should be immediately administered8. Biologic drugs act against specific cytokines or their receptors, in order to reduce tissue damage9. Currently, infliximab, and adalimumab are the main TNF inhibitors available for children10 and are used in the treatment of refractory or chronic childhood uveitis 11,12 . Our study aims to analyze the value and outcome of using biologics at Abou el Reesh, Cairo University Hospital, being a main tertiary referral center in Egypt for children with JIA-U.
Interventions
DRUGbiologic DMARDs
follow up the clinical response in Egyptian population to the drug
Sponsors
Kasr El Aini Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Months to 16 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed JIA according to rheumatological criteria with ocular affection * Any type of arthritis (oligoarticular, polyarticular, systemic onset, ocular JIA) * ANA positive or negative * Uncontrolled uveitis or frequent relapses
Exclusion criteria
* Patients without definitive diagnosis as JIA * JIA patients on biologics without ocular affection (for systemic control) or with uveitis controlled without the use of biologics * Patients without adequate duration for follow-up (less than 3 months) or lost follow up data * Patients without available data prior to the start biologics (to compare control of the uveitis)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| steroids sparing effect of the drug | 24 months | reduction in the dosage/frequency of topical and systemic steroids |
| the severity and complications of the uveitis | 24 months | degree of clinical improvement by clinical examination |
Countries
Egypt
Outcome results
None listed